Dicerna Pharmaceuticals Inc

NASDAQ:DRNA

26.06

-0.36 (-1.36%)

Market Cap (Intraday)	1.96B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$46.52 Million
Adjusted EPS	-$0.41

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Dicerna Pharmaceuticals, Inc. Stock, NASDAQ:DRNA

33 Hayden Avenue, Lexington, Massachusetts 02421

United States of America

Phone: +1.617.621.8097

Number of Employees: 187

http://www.dicerna.com

Description

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.